Weekly paclitaxel in elderly patients with advanced breast cancer: A dose-finding study

Drugs in R and D

Volumn 5, Issue 1, 2004, Pages 11-15

  Repetto, Lazzaro ^a   Comandini, Danila ^b   Mammoliti, Sonia ^b   Pietropaolo, Maria ^c   del Mastro, Lucia ^b  

^a INRCA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; ORPHENADRINE; PACLITAXEL; RANITIDINE; TAMOXIFEN;

ADVANCED CANCER; AGE; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

AGED; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; PACLITAXEL;

EID: 1042292649     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200405010-00002     Document Type: Article

References (32)

1. Klimmick GG, Balducci L. Breast cancer and aging: clinical interactions. Hematol Oncol Clin North Am 2000; 14: 213-34
2. Alberg AJ, Singh S. Epidemiology of breast cancer in older women: implications for future healthcare. Drugs Aging 2001; 18 (10): 761-72
3. Daidone MG, Luisi A, Martelli G, et al. Biomarkers and outcomes after tamoxifen treatment in node-positive breast cancers from elderly women. Br J Cancer 2000; 82: 270-7
4. Repetto L, Fratino L, Audisio RA, et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group Performance Status in elderly cancer patients: an Italian Group for Geriatric Oncology study. J Clin Oncol 2002; 20 (2): 494-502
5. Fennelly D, Aghajanian C, Shapiro F, et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997; 15: 187-92
6. Klaassen U, Wilke H, Strumberg D, et al. Phase I study with a weekly 1-h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer. Eur J Cancer 1996; 32A: 547-9
7. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 1990; 82: 1247-59
8. Seidman AD, Tiersten A, Hudis C, et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 1995; 13: 2575-81
9. Davidson NG. Single-agent paclitaxel as first-line treatment of metastatic breast cancer: the British experience. Semin Oncol 1996; 23 Suppl. 11: 6-10
10. Abrams JS, Vena DA, Baltz J, et al. Paclitaxel activity in heavily pretreated breast cancer; a National Cancer Institute Treatment Referral Center trial. J Clin Oncol 1995; 13: 2056-65
11. Seidman AD, Reichman BS, Crown JP, et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 1995; 13: 1152-9
12. Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995; 13: 2688-99
13. Sledge GW, Neuberg D, Ingle J, et al. Phase III trial of doxorubicin vs paclitaxel vs doxorubicin + paclitaxel as first line therapy for metastatic breast cancer: an Intergroup trial [abstract]. Proc Am Soc Clin Oncol 1997; 16: 1a
14. Jassem J, Pienkowski T, Pluzanska A, et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 2001; 19: 1707-15
15. Fountzilas G, Athanassiades A, Giannakakia T, et al. A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines. Eur J Cancer 1996; 32: 47-51a
16. Nabholtz JM, Gelmon K, Bontebal M, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996; 14: 1858-67
17. Waintraub SE, Cantwell S, DeVries J, et al. Phase II study to evaluate the efficacy of weekly paclitaxel (WP) in patients with metastatic breast cancer who have failed prior anthracycline (A) +/- taxane therapy. Proc Am Soc Clin Oncol 2000; 19: 121a
18. Sola C, Lluch A, Garcia-Conde J, et al. Phase II study of weekly paclitaxel (P) treatment in recurrent breast cancer after high-dose chemotherapy [abstract]. Proc Am Soc Clin Oncol 1999; 18: 65a
19. Mickiewicz E, Alvarez AM, Brosio C, et al. Reinduction second line treatment with weekly taxol in anthracycline recurrent, advanced breast cancer patients [abstract]. Proc Soc Am Clin Oncol 1999; 18: 135a
20. Alvarez AM, Mickiewicz E, Brosio C, et al. Reinduction of response with weekly taxol in advanced breast cancer [abstract 636]. Proc Soc Am Clin Oncol 1999; 18: 135a
21. Breier S, Lebedinsky C, Ayuvuru A, et al. Long-term weekly paclitaxel in metastatic breast cancer: a phase II trial in pretreated patients [abstract]. Proc Soc Am Clin Oncol 1998; 17: 192a
22. Seidman AD. One-hour paclitaxel via weekly infusion: dose-density with enhanced therapeutic index. Oncology (Hunting) 1998 Jan; 12 (1 Suppl. 1): 19-22
23. Seidman AD, Hudis CA, Albanel J, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998; 16: 3353-61
24. 2 in pretreated patients with breast and ovarian cancer [abstract]. Proc Am Soc Clin Oncol 1997; 16: 163a
25. Akerley W, Sikov WM, Cummings F, et al. Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report. Semin Oncol 1997 Oct; 24 (5 Suppl. 17): S87-90
26. Akerley W. Paclitaxel in advanced non-small cell lung cancer: an alternative high-dose weekly schedule. Chest 2000; 117 (4 Suppl. 1): 152S-5S
27. Chang AY, Boros L, Asbury R, et al. Dose-escalation study of weekly 1-hour paclitaxel administration in patients with refractory cancer. Semin Oncol 1997 Oct; 24 (5 Suppl. 17): S17-69-S17-71
28. Klaassen U, Wilke H, Strumberg D, et al. Phase I study with a weekly 1h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer. Eur J Cancer 1996 Mar; 32A (3): 547-9
29. Fennelly D, Shapiro F, Aghajanian C, et al. Dose-intensive paclitaxel delivery utilizing a weekly one-hour infusion schedule: efficacy and feasibility in patients with persistent ovarian cancer [abstract]. Proc Ann Meet Am Soc Clin Oncol 1996; 15: A777
30. Loeffler TM, Freund W, Lipke J, et al. Schedule and dose intensified paclitaxel as weekly one hour infusion. Evidence for an improved toxicity profile and response activity in pretreated solid tumors [abstract]. Proc Ann Meet Am Soc Clin Oncol 1995; 14: A1522
31. Rosenberg P, Andersson H, Boman K, et al. A randomized multicenter study of single agent paclitaxel (Taxol®) given weekly versus every three weeks to patients with ovarian cancer previously treated with platinum therapy [abstract]. Proc Ann Meet Am Soc Clin Oncol 1999; 18: A1420
32. Perez EA, Vogel CL, Irwin DH, et al. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 2001; 19 (22): 4216-23